Novo Nordisk's (NVO) obesity therapy Wegovy cut adverse kidney-related events by 22% in obese and overweight individuals in a ...

Novo Nordisk’s blockbuster GLP-1 analog Wegovy (semaglutide) can maintain meaningful weight loss for up to four years and improve cardiovascular health regardless of the amount of weight lost, ...

Patients taking Novo Nordisk's obesity drug Wegovy maintained an average of 10% weight loss for up to four years, according to a new analysis from the longest clinical trial to date on the treatment.

LONDON (Reuters) -Patients taking Novo Nordisk's Wegovy obesity treatment maintained an average of 10% weight loss after four years, potentially boosting the drugmaker's case to insurers and ...

Novo Nordisk, the pharmaceutical company behind Ozempic, has launched a national campaign promoting its injectable ...

LONDON - Patients taking Novo Nordisk’s Wegovy obesity treatment maintained an average of 10 per cent weight loss after four years, potentially boosting the drugmaker’s case to insurers and ...

Patients using Novo Nordisk’s NVO NONOF obesity treatment, Wegovy, have reportedly maintained an average weight loss of 10% over a four-year period, as per data revealed by the company on Tuesday.

Newly released clinical trial data on the GLP-1 agonist drug Wegovy found that weight loss was sustained for up to four years after participants started taking the once-weekly injected medication.

FAT jabs could be the cancer hope of the future after early studies found they reduce the risk of tumours. The world’s top ...